卵巢癌中肿瘤标志物血清水平与基因产物组织表达的关系。

Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma.

作者信息

Sorak M, Arsenijević S, Lukić G, Arsenijević N, Ristić P, Pavlović S, Popović S, Baskić D

机构信息

Clinic for Gynecology and Obstetrics, Clinical Centre, Kragujevac, Serbia.

出版信息

J BUON. 2007 Jan-Mar;12(1):99-104.

PMID:17436409

Abstract

PURPOSE

The aim of this prospective study was to determine serum levels and tissue expression of CA125, CA 15-3, p53, HER-2 and nm23 tumor markers, which are used in the detection and follow up of patients with ovarian carcinoma.

PATIENTS AND METHODS

19 patients with malignant and benign ovarian tumors were included in this study. Serum levels of CA125, CA 15-3 and p53 tumor markers were detected in preoperative and postoperative blood samples using ELISA technique. Tissue expression of p53, HER-2 and nm23 were examined using immunohistochemistry.

RESULTS

All serum tumor markers were elevated in patients with ovarian carcinoma. Serum level of CA 15-3 was increased in patients with ovarian carcinoma (median 48.33 U/ml, normal range 0-36), while it was normal in patients with benign ovarian tumors (median 20.67 U/ml; p >0.05). CA125 serum values were strikingly increased in ovarian carcinoma (median 264.16 IU/ml, normal range 0-35) and benign ovarian tumors (median 119.59 IU/ml; p <0.05). Serum levels of p53 in patients with ovarian carcinoma were increased (median 0.69 U/ml, normal range 0-0.50) compared to patients with benign tumors (0.32 U/ml; p <0.05). Histological HER-2 overexpression was detected in 7 cases, including 4 with strong (score 3+ and 2+) and 3 with weak or no HER-2 expression (score 1+ and 0) in ovarian carcinoma tissue; in benign tumors HER-2 overexpression was detected in 1 case (p >0.05). Strong overexpression of p53 was detected in 3 cases with malignant and none with benign tumors (p >0.05); and strong overexpression of nm23 was detected in 5 cases with malignant and 2 with benign tumors (p >0.05).

CONCLUSION

Serum levels of CA125, CA 15-3 and p53 are strikingly increased, as well as the expression of HER-2 and p53 in carcinomatous tissue. Detection and analysis of multiple tumor-specific markers in serum and tissue can give useful clinical information for the management of ovarian carcinoma and can also improve the sensitivity and specificity of these markers.

摘要

目的

本前瞻性研究旨在测定CA125、CA 15 - 3、p53、HER - 2和nm23肿瘤标志物的血清水平及组织表达情况，这些标志物用于卵巢癌患者的检测和随访。

患者与方法

本研究纳入了19例患有恶性和良性卵巢肿瘤的患者。采用ELISA技术检测术前和术后血样中CA125、CA 15 - 3和p53肿瘤标志物的血清水平。采用免疫组织化学方法检测p53、HER - 2和nm23的组织表达。

结果

卵巢癌患者所有血清肿瘤标志物均升高。卵巢癌患者CA 15 - 3血清水平升高（中位数48.33 U/ml，正常范围0 - 36），而良性卵巢肿瘤患者CA 15 - 3血清水平正常（中位数20.67 U/ml；p>0.05）。卵巢癌患者CA125血清值显著升高（中位数264.16 IU/ml，正常范围0 - 35），良性卵巢肿瘤患者CA125血清值也升高（中位数119.59 IU/ml；p<0.05）。与良性肿瘤患者（0.32 U/ml；p<0.05）相比，卵巢癌患者p53血清水平升高（中位数0.69 U/ml，正常范围0 - 0.50）。在7例卵巢癌组织中检测到组织学HER - 2过表达，其中4例为强过表达（评分3 +和2 +），3例为弱或无HER - 2表达（评分1 +和0）；在良性肿瘤中，仅1例检测到HER - 2过表达（p>0.05）。3例恶性肿瘤患者检测到p53强过表达，良性肿瘤患者均未检测到（p>0.05）；5例恶性肿瘤患者和2例良性肿瘤患者检测到nm23强过表达（p>0.05）。